Search

Highlights of Past EHA (HOPE) MENA 2021

For the upcoming edition of the Highlights of Past EHA (HOPE) Middle East and North Africa (MENA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Cancer Medicines Forum workshop April 5: a way forward for treatment optimization

The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

Read more

Join EHA and SIE and receive up to €50 discount on your EHA membership

We are pleased to inform you that EHA and the Società Italiana di Ematologia (SIE) have joined forces and are offering you the possibility of an EHA-SIE Joint Membership.

Read more

EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes

The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.

Read more

FUNDING ALERT: Calls published on ATMPs, T cells and cancer research

In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists:

1.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more